Lianhuan Pharmaceutical: The LH-1801 project faces significant uncertainties at multiple critical stages from successful clinical trials to final market launch and profitability.

Jin10 data reported on July 8th that Lianhuan Pharmaceutical issued an announcement regarding abnormal fluctuations in stock trading. The LH-1801 project clinical trial adopts a non-inferiority design, and there is significant uncertainty regarding whether the target can ultimately be achieved. The LH-1801 project faces significant uncertainties in multiple key segments from successful clinical trials to final market launch and profitability. The LH-1801 project is currently still in the R&D stage and is expected to not have a significant impact on the company's operating income and performance for a considerable period of time.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)